PINK:GTHP

Guided Therapeutics Stock Insider Trading

Healthcare > Medical - Devices

Buy GTHP

*Your capital is at risk

$0.228

+0 (+0%)

At Close: Jun 03, 2026

Guided Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 83.10. In total, the insiders bought 27.53M and sold 552.63M GTHP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	83.10
● Buy	27.53M shares
● Sell	552.63M shares
74% Buy Activity Weak Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 25, 2026 Buy	Warrants M-Exempt	Blumberg Richard P.	Director	1 000 000 Value: $200.0K
Feb 25, 2026 Buy	Warrants J-Other	Imhoff John E	Director	500 000 Value: $325.0K
Feb 25, 2026 Buy	Common Stock X-InTheMoney	Imhoff John E	Director	500 000 Value: $150.0K
Feb 25, 2026 Buy	Warrants J-Other	Imhoff John E	Director	500 000 Value: $100.0K
Feb 25, 2026 Sell	Warrants J-Other	Imhoff John E	Director	500 000 Value: $325.0K
Feb 25, 2026 Sell	Warrants J-Other	Imhoff John E	Director	500 000 Value: $250.0K
Feb 25, 2026 Sell	Warrants X-InTheMoney	Imhoff John E	Director	500 000 Value: $100.0K
Feb 25, 2026 Sell	Warrants J-Other	James Michael C Director	Director	100 000 Value: $50.0K
Feb 25, 2026 Sell	Warrants X-InTheMoney	James Michael C Director	Director	100 000 Value: $25.0K
Feb 25, 2026 Buy	Common Stock X-InTheMoney	James Michael C Director	Director	100 000 Value: $65.0K
Feb 25, 2026 Buy	Warrants J-Other	James Michael C Director	Director	100 000 Value: $25.0K
Feb 25, 2026 Buy	Warrants J-Other	James Michael C Director	Director	100 000 Value: $50.0K
Feb 25, 2026 Sell	Warrants J-Other	James Michael C Director	Director	100 000 Value: $65.0K
Feb 02, 2026 Sell	Convertible Promissory Note C-Conversion	Imhoff John E	Director	312 720 Value: $21.9K
Feb 02, 2026 Buy	Common Stock C-Conversion	Imhoff John E	Director	312 720 Value: $21.9K
Jan 05, 2026 Buy	Common Stock J-Other	Imhoff John E	Director	25 338 Value: $11.7K
Dec 18, 2025 Buy	Common Stock C-Conversion	Imhoff John E	Director	195 460 Value: $13.7K
Dec 18, 2025 Sell	Convertible Promissory Note C-Conversion	Imhoff John E	Director	195 460 Value: $13.7K
Aug 29, 2025 Buy	Common Stock P-Purchase	Grujic Alan Director	Director	152 108 Value: $38.7K
Aug 29, 2025 Buy	Warrants P-Purchase	Grujic Alan Director	Director	152 108 Value: $38.0K
Aug 29, 2025 Buy	Common Stock P-Purchase	Imhoff John E	Director	166 667 Value: $30.0K
Aug 29, 2025 Buy	Warrants P-Purchase	Imhoff John E	Director	166 667 Value: $41.7K
Aug 29, 2025 Buy	Common Stock P-Purchase	James Michael C Director	Director	27 778 Value: $5K
Aug 29, 2025 Buy	Warrants P-Purchase	James Michael C Director	Director	27 778 Value: $7K
Aug 29, 2025 Buy	Warrants P-Purchase	James Michael C Director	Director	27 778 Value: $7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GUIDED THERAPEUTICS, INC.

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its n...

Read Full Profile Here